We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Dose Escalation Trial of BNT152+153 in Patients With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04710043
Recruitment Status : Recruiting
First Posted : January 14, 2021
Last Update Posted : May 31, 2023
Information provided by (Responsible Party):
BioNTech SE

Brief Summary:

This is an open-label, multisite Phase I dose escalation, safety, pharmacokinetics (PK) and pharmacodynamics (PD) trial of BNT152+153 in various solid tumor indications.

The clinical trial will enroll patients with various solid tumors that are metastatic or unresectable for whom there is no available standard therapy likely to confer clinical benefit, or patients who are not candidates for such available therapy.

The trial consists of Part 1 and Part 2 with adaptive design elements:

  • Part 1 consists of Groups A and B.

    • Group A is a BNT153 monotherapy dose escalation in patients with advanced solid malignancies until the maximal tolerated dose (MTD) is defined. If MTD is not reached, maximum administered dose (MAD) may be used for further development (or another dose as determined by the safety review committee [SRC]).
    • Group B is a BNT152 monotherapy dose escalation in patients with advanced solid malignancies until the MTD or optimal biological dose (OBD; the lowest safe dose associated with optimal biological activity) is defined, whichever occurs earlier.
    • Group A will be activated first while the time point for Group B activation is at sponsor's decision.
  • This trial also plans to implement biomarker expansion cohorts after BNT153 and/or BNT152 dose escalation is completed. The Biomarker Cohorts will recruit patients at selected sites.
  • Part 2 will start once the MTD/MAD have been established for BNT153 and OBD for BNT152 in Part 1.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: BNT152 Drug: BNT153 Phase 1

Detailed Description:
This trial will be conducted in the US with the potential to open to other countries in the future.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 112 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I, First-in-human, Open-label, Dose Escalation Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of BNT152+153 in Patients With Solid Tumors
Actual Study Start Date : June 8, 2021
Estimated Primary Completion Date : October 2023
Estimated Study Completion Date : October 2023

Arm Intervention/treatment
Experimental: Part 1 group A BNT153
Monotherapy dose escalation.
Drug: BNT153
intravenous (IV)

Experimental: Part 1 group B BNT152
Monotherapy dose escalation.
Drug: BNT152

Primary Outcome Measures :
  1. Occurrence of treatment-emergent adverse events (TEAEs) including Grade ≥ 3, serious, fatal TEAE by causal relationship to trial treatment [ Time Frame: up to 24 months ]
    TEAEs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.5.0.

  2. Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) within a patient due to TEAE [ Time Frame: up to 24 months ]
  3. Occurrence of dose limiting toxicities (DLTs) during the DLT evaluation period - BNT152 [ Time Frame: 21 days ]
  4. Occurrence of DLTs during the DLT evaluation period - BNT153 [ Time Frame: 21 days ]

Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: up to 24 months ]
    ORR is defined as the proportion of patients in whom a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) is observed as best overall response.

  2. Disease control rate (DCR) [ Time Frame: up to 24 months ]
    DCR is defined as the proportion of patients in whom a CR or PR or stable disease (SD) (per RECIST 1.1, SD assessed at least 6 weeks after first dose) is observed as best overall response.

  3. Duration of response (DOR) [ Time Frame: up to 24 months ]
    DOR is defined as the time from first overall response (CR or PR per RECIST 1.1) to first occurrence of objective tumor progression (progressive disease (PD) per RECIST 1.1) or death from any cause, whichever occurs first.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed solid tumor that is metastatic (Stage IV) or unresectable and for whom there is no available standard therapy likely to confer clinical benefit, or patient who is not a candidate for such available therapy. If there is no contraindication, patients should have exhausted all standard of care (SoC) therapies before entering the trial.
  • Measurable or evaluable disease per RECIST1.1.
  • Male and female aged ≥ 18 years.
  • Prior to any trial-related assessments or procedures, must sign an informed consent form (ICF) indicating that he or she understands the purpose and procedures required for the trial and are willing to participate in the trial.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • Adequate coagulation function at screening as determined by:

    1. International normalized ratio (INR) or prothrombin time ≤ 1.5 × upper limit normal (ULN); unless on therapeutic anticoagulants with values within therapeutic window),
    2. Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (unless on therapeutic anticoagulants with values within therapeutic window).
  • Adequate hematologic function at screening as determined by:

    1. White blood cell count (WBC) ≥ 3 × 10^9/L
    2. Absolute neutrophil count ≥ 1.5 × 10^9/L (patient may not use granulocyte-colony stimulating factor (G-CSF) or granulocyte-macrophage colony stimulating factor (GM-CSF) to achieve these WBC and absolute neutrophil count levels)
    3. Platelet count ≥ 100 × 10^9/L
    4. Hemoglobin (Hgb) ≥ 9.0 g/dL
  • Adequate hepatic function at screening as determined by:

    1. Total bilirubin ≤ 1.5 mg/dL (or ≤ 2.0 mg/dL for patients with known Gilbert's syndrome or liver metastasis)
    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; ≤ 3 × ULN for patients with liver metastasis.
  • Adequate renal function at screening as determined by: Glomerular filtration rate (GFR) ≥ 45 mL/min/1.73 m^2 - according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, expressed as a single equation: GFR = 141 × min(Scr/κ,1)^α × max(Scr/κ, 1)^-1.209 × 0.993^Age × 1.018 [if female] × 1.159 [if black]; Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. For creatinine assays using methods traceable to isotope dilution mass spectrometry (IDMS) assigned National Institute of Standards and Technology (NIST) certified reference materials (Levey et al. 2009).
  • Able and willing to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions, and other requirements of the trial.
  • Women of childbearing potential (WOCBP) must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) test/value at screening. Patients who are post-menopausal or permanently sterilized can be considered as not having reproductive potential.
  • WOCBP must agree to use highly effective contraception during the trial and for 6 months after receiving the last dose of BNT152 or BNT153. Birth control methods are considered highly effective if they have a failure rate of less than 1% per year, when used consistently and correctly.
  • WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire trial, until 6 months after last BNT152 or BNT153 treatment.
  • A man who is sexually active with a WOCBP and has not had a vasectomy must agree to use a barrier method of birth control, e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also agree to not donate sperm during the trial and for 6 months after receiving the last dose of BNT152 or BNT153.
  • For enrollment into the Biomarker Cohorts only: At selected sites only: at enrollment patients must agree to have one pre-dose biopsy (baseline) and at least a lesion that is deemed accessible by the investigator which is different from the target lesion. Patients must also agree to at least one on-treatment biopsy (preferred C2D5-12) from same tumor lesion.

Exclusion Criteria:

Prior and concomitant therapy:

  • Use of any investigational medical product or device within 28 days before administration of first dose of trial treatment.
  • Has been receiving: radiotherapy, chemotherapy, or molecularly-targeted agents or tyrosine kinase inhibitors within 2 weeks or 5 half-lives (whichever is longer) of the start of trial treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of trial treatment; nitrosourea, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of trial treatment.
  • Ongoing participation in the active treatment phase of an interventional clinical trial.
  • Receives concurrent systemic (oral or IV) steroid therapy >10 mg prednisone daily or its physiological equivalent for an underlying condition.
  • Has had major surgery within the 4 weeks before the first dose of trial treatment.
  • Ongoing or active infection requiring IV treatment with anti-infective therapy that has been administered less than 2 weeks prior to the first dose of trial treatment.
  • Has side effects of any prior therapy or procedures for any medical condition not recovered to NCI CTCAE v.5 Grade ≤ 1. Note: peripheral neuropathy Grade ≤ 2 is allowed; alopecia of any grade is allowed.

Medical conditions:

  • Current evidence of new or growing brain or leptomeningeal metastases during screening. Patients with known brain metastases may be eligible if they:

    1. had radiotherapy, surgery or stereotactic surgery for the brain metastases,
    2. have no neurological symptoms (excluding Grade ≤ 2 neuropathy),
    3. have stable brain metastasis on the computerized tomography (CT) or magnetic resonance imaging (MRI) scan within 4 weeks before signing the informed consent,
    4. are not undergoing acute corticosteroid therapy or steroid taper. Notes: Patients with central nervous system (CNS) symptoms should undergo a CT-scan or MRI of the brain to exclude new or progressive brain metastases. Spinal bone metastases are allowed, unless imminent fracture with cord compression is anticipated.
  • Has a history of a cerebrovascular accident or had a transient ischemic attack less than 6 months before signing the ICF.
  • Effusions (pleural, pericardial, or ascites) requiring drainage.
  • Active autoimmune disease including but not limited to inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis (except type 1 diabetes with well-regulated blood sugar).
  • Has any active immunologic disorder or after organ transplantation requiring immunosuppression with steroids or other immunosuppressive agents (e.g., azathioprine, cyclosporine A) with the exception of patients with isolated vitiligo, resolved childhood asthma or atopic dermatitis, controlled hypoadrenalism or hypopituitarism, and patients with a history of Graves' disease with stable thyroid function. Patients with controlled hyperthyroidism must be negative for thyroglobulin, thyroid peroxidase antibodies, and thyroid stimulating immunoglobulin prior to administration of trial treatment.
  • Known history of seropositivity for human immunodeficiency virus (HIV) with CD4+ T˗cell (CD4+) counts <350 cells/µL and with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections.
  • Known history/positive serology for hepatitis B requiring active antiviral therapy (unless immune due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy). Patients with positive serology must have hepatitis B virus viral load below the limit of quantification.
  • Active hepatitis C virus infection; patients who have completed curative antiviral treatment with hepatitis C virus viral load below the limit of quantification are allowed.
  • Known hypersensitivity to a component of any trial treatment.
  • Another primary malignancy that has not been in remission for at least 2 years, with the exception of those with a negligible risk of metastasis or death (including but not limited to adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ). In case of uncertainties, the medical monitor should be consulted.

Other comorbidities:

  • Abnormal electrocardiograms (ECGs) that are clinically significant, such as Fridericia-corrected QT prolongation >480 ms.
  • In the opinion of the treating investigator, has any concurrent conditions that could pose an undue medical hazard or interfere with the interpretation of the trial results; these conditions include, but are not limited to:

    1. Ongoing or active infection requiring antibiotic/antiviral/antifungal therapy.
    2. Concurrent congestive heart failure (New York Heart Association [NYHA] Functional Classification Class III or IV).
    3. Concurrent unstable angina.
    4. Concurrent cardiac arrhythmia requiring treatment (excluding asymptomatic atrial fibrillation).
    5. Acute coronary syndrome within the previous 6 months.
    6. Symptomatic pulmonary embolism within the previous 3 months.
    7. Significant pulmonary disease (shortness of breath at rest or on mild exertion) for example due concurrent severe obstructive pulmonary disease.
  • Cognitive, psychological or psychosocial impediment that would impair the ability of the patient to receive therapy according to the protocol or adversely affect the ability of the patient to comply with the informed consent process, protocol, or protocol-required visits and procedures.
  • Is pregnant or breastfeeding.
  • Patients unable to consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04710043

Layout table for location contacts
Contact: BioNTech clinical trials patient information +49 6131 9084 ext 0 patients@biontech.de

Layout table for location information
United States, Connecticut
Yale Cancer Center Recruiting
New Haven, Connecticut, United States, 06510
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
United States, North Carolina
Duke Cancer Center Recruiting
Durham, North Carolina, United States, 27710
United States, Tennessee
Sarah Cannon Research Institute at Tennessee Oncology Recruiting
Nashville, Tennessee, United States, 37203
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
NEXT Oncology Recruiting
San Antonio, Texas, United States, 78229
Masaryk Memorial Cancer Institute Recruiting
Brno, Czechia, 65653
Sponsors and Collaborators
BioNTech SE
Layout table for investigator information
Study Director: BioNTech Responsible Person BioNTech SE
Layout table for additonal information
Responsible Party: BioNTech SE
ClinicalTrials.gov Identifier: NCT04710043    
Other Study ID Numbers: BNT152-01C
2021-005599-20 ( EudraCT Number )
First Posted: January 14, 2021    Key Record Dates
Last Update Posted: May 31, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BioNTech SE:
BioNTech SE
Solid Tumors
Advanced solid malignancies